Day One Biopharmaceuticals

SpringWorks Therapeutics

This biopharmaceutical company develops and commercialises targeted oncology medicines and therapies for patients with rare diseases and cancer.

Oncopeptides AB

This biotech company develops targeted therapies for patients with difficult-to-treat hematological diseases, specifically focusing on multiple myeloma treatments.

Scorpion Therapeutics

This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.

Black Diamond Therapeutics

This clinical-stage company develops precision oncology medicines and small molecule therapies for patients with genetically defined cancers.

Fore Biotherapeutics

This precision oncology company develops targeted therapies for patients with unaddressed cancer mutations, including a specific BRAF inhibitor for advanced solid tumours.

Syndax

This biopharmaceutical company develops and commercialises targeted therapies for adult and paediatric patients with cancer and chronic graft-versus-host disease.

Sartar Therapeutics

This company develops targeted cancer therapies for patients with gastrointestinal stromal tumours and other soft tissue sarcomas.

Olema Oncology

This biopharmaceutical company develops targeted therapies, including palazestrant, for women diagnosed with estrogen receptor-positive breast cancer and other solid tumours.